Mira Chaurushiya

Novome is building genetically engineered microbial medicines (GEMMs) that perform defined activities in the human gut to treat chronic diseases. We have developed the first platform for controlled colonization of the gut with engineered therapeutic bacteria, and are applying this to multiple disease areas as well as expanding our platform capabilities. Our lead program in enteric hyperoxaluria is currently in Phase 2 clinical trials, and we are focusing current research efforts on making a microbial cell therapy to treat inflammatory bowel disease (IBD).

𝗧𝗛𝗘 𝗡𝗘𝗫𝗧 𝗚𝗘𝗡𝗘𝗥𝗔𝗧𝗜𝗢𝗡 𝗢𝗙 𝗘𝗚𝗚 𝗔𝗡𝗗 𝗘𝗠𝗕𝗥𝗬𝗢 𝗦𝗧𝗢𝗥𝗔𝗚𝗘 TMRW Life Sciences is a fertility technology company that provides safety and transparency to modernize and transform egg and embryo storage.   The current system is manual, outdated, and stressful for embryologists and clinicians. Automatization and state-of-the-art technology identify, track and remotely monitor frozen eggs and embryos. TMRW is a scalable solution for overcrowded clinics that have unintentionally become storage facilities since the rise in people seeking fertility treatments. Named Fast Company's #1 Most Innovative Biotech Company in 2022, TMRW is in leading clinics across the US and will soon be available in the UK and Europe.

IDEAYA is an oncology-focused precision medicine company. Our teams are committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. We are advancing therapeutics that have the potential to be first-in-class and/or best-in-class, with a primary focus in synthetic lethality – an emerging class of precision medicine targets. IDEAYA is headquartered in South San Francisco, California.

Escient is a clinical-stage pharmaceutical company focused on developing novel therapeutics to address a broad range of neurosensory-inflammatory diseases. Our pipeline includes two first-in-class small molecule antagonists targeting MRGPRX2 for the treatment of various mast cell-mediated disorders and MRGPRX4 for cholestatic pruritus. Based in San Diego, California, Escient is led by an experienced team with specific expertise in GPCR drug discovery and development and funded by top-tier life science investors.

NodThera is developing a new class of potent and highly selective NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation. We’re building a dynamic team of people across our offices in Cambridge, UK; Seattle, WA; and Boston, MA; all united by our shared ambition, enthusiasm, and creativity.

BlueLight Therapeutics leverages a proprietary, structure-driven platform to develop new small molecule therapeutics against challenging, high-value drug targets.

BlueLight Therapeutics leverages a proprietary, structure-driven platform to develop new small molecule therapeutics against challenging, high-value drug targets.

PNI is a global leader in ushering in the next wave of genetic medicines in infectious diseases, cancer, and rare diseases. We work with the world’s leading drug developers to understand disease and create the therapeutics and vaccines that will define the future of medicine. PNI offers proprietary technology platforms and comprehensive expertise to enable researchers to translate disease biology insights into non-viral genetic medicines.

Our firm brings Silicon Valley access and experience to Los Angeles, an emerging biotech community that is fresh, unorthodox and exciting. We are playing our part catalyzing the biopharma industry not just in the LA region but beyond. Technology can come from anywhere and we match our company building skills with interested entrepreneurs or academic centers.

5AM was founded in 2002 and pursues investments in advanced life science innovations, and seeks to be diversified across the biopharmaceutical therapeutics, and platform technologies. Within each sector, 5AM invests across multiple therapeutic areas and modalities and evaluates opportunities based on innovative platform technologies, corporate spin-offs and products with shorter development cycles. Content 5AM shares on this platform is not, and may not be relied on, in any manner, as legal, tax, investment, accounting or other advice or as an offer to sell or a solicitation of an offer to buy an interest in any private fund, special purpose or other investment vehicle sponsored by 5AM Ventures. Content 5AM shares on this platform is not an investment recommendation. For a full list of all 5AM portfolio companies, please visit: https://5amventures.com/portfolio/

Novome is building genetically engineered microbial medicines (GEMMs) that perform defined activities in the human gut to treat chronic diseases. We have developed the first platform for controlled colonization of the gut with engineered therapeutic bacteria, and are applying this to multiple disease areas as well as expanding our platform capabilities. Our lead program in enteric hyperoxaluria is currently in Phase 2 clinical trials, and we are focusing current research efforts on making a microbial cell therapy to treat inflammatory bowel disease (IBD).

𝗧𝗛𝗘 𝗡𝗘𝗫𝗧 𝗚𝗘𝗡𝗘𝗥𝗔𝗧𝗜𝗢𝗡 𝗢𝗙 𝗘𝗚𝗚 𝗔𝗡𝗗 𝗘𝗠𝗕𝗥𝗬𝗢 𝗦𝗧𝗢𝗥𝗔𝗚𝗘 TMRW Life Sciences is a fertility technology company that provides safety and transparency to modernize and transform egg and embryo storage.   The current system is manual, outdated, and stressful for embryologists and clinicians. Automatization and state-of-the-art technology identify, track and remotely monitor frozen eggs and embryos. TMRW is a scalable solution for overcrowded clinics that have unintentionally become storage facilities since the rise in people seeking fertility treatments. Named Fast Company's #1 Most Innovative Biotech Company in 2022, TMRW is in leading clinics across the US and will soon be available in the UK and Europe.

5AM was founded in 2002 and pursues investments in advanced life science innovations, and seeks to be diversified across the biopharmaceutical therapeutics, and platform technologies. Within each sector, 5AM invests across multiple therapeutic areas and modalities and evaluates opportunities based on innovative platform technologies, corporate spin-offs and products with shorter development cycles. Content 5AM shares on this platform is not, and may not be relied on, in any manner, as legal, tax, investment, accounting or other advice or as an offer to sell or a solicitation of an offer to buy an interest in any private fund, special purpose or other investment vehicle sponsored by 5AM Ventures. Content 5AM shares on this platform is not an investment recommendation. For a full list of all 5AM portfolio companies, please visit: https://5amventures.com/portfolio/